This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the protocol is to evaluate oral valganciclovir in neonates with sypmtomatic congenital cytomegalovirus infections involving the central nervous system. (IND#63,289) Ganciclovir treatment of neonates with symptomatic congenital CMV disease involving the CNS indicates that ganciclovir therapy both improves hearing function (or maintains normal hearing) and prevents hearing deterioration at 6 months. The recent development of a syrup formulation of valganciclovir, the orally bioavailable prodrug of ganciclovir, provides a unique opportunity to seek to build upon the successes of antibiral intervention in this devastating illness.
Showing the most recent 10 out of 570 publications
